Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019024933) GPC3-TARGETED CAR NK CELL
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/024933 International Application No.: PCT/CN2018/098623
Publication Date: 07.02.2019 International Filing Date: 03.08.2018
IPC:
C12N 5/10 (2006.01) ,C07K 16/28 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10
Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
Applicants:
科济生物医药(上海)有限公司 CARSGEN THERAPEUTICS CO., LTD. [CN/CN]; 中国上海市 徐汇区银都路388号B栋 Building B, No. 388 Yindu Raod, Xuhui District Shanghai 200231, CN
上海市肿瘤研究所 SHANGHAI CANCER INSTITUTE [CN/CN]; 中国上海市 徐汇区斜土路2200弄25号 No. 25/Ln 2200 Xietu Road, Xuhui District Shanghai 200032, CN
Inventors:
李宗海 LI, Zonghai; CN
喻敏 YU, Min; CN
高慧萍 GAO, Huiping; CN
Agent:
上海一平知识产权代理有限公司 XU & PARTNERS, LLC.; 中国上海市 普陀区真北路958号天地科技广场1号楼106室 Room 106, Building No. 1 Universal High-Tech Plaza 958 Zhen Bei Road, Putuo District Shanghai 200333, CN
Priority Data:
201710661765.304.08.2017CN
Title (EN) GPC3-TARGETED CAR NK CELL
(FR) CELLULE CAR NK CIBLANT GPC3
(ZH) 靶向GPC3的CAR NK细胞
Abstract:
(EN) Provided is a chimeric antigen receptor NK cell expressing specific recognition for GPC3 and preparation method therefor, as well as a use of the cell in prevention and/or treatment of cancers, especially a GPC3-expression cancer. Also provided is a use of the NK cell as a targeting cell therapeutic agent and/or in adoptive immunotherapy of cancers.
(FR) L'invention concerne une cellule NK à récepteur d'antigène chimérique exprimant une reconnaissance spécifique pour GPC3 et sa méthode de préparation, ainsi qu'une utilisation de la cellule dans la prévention et/ou le traitement de cancers, en particulier un cancer exprimant GPC3. L'invention concerne également une utilisation de la cellule NK en tant qu'agent thérapeutique cellulaire de ciblage et/ou en immunothérapie adoptive de cancers.
(ZH) 提供了一种表达特异性识别GPC3的嵌合抗原受体的NK细胞,其制备方法,以及该细胞在预防和/或治疗癌症,尤其是GPC3表达癌症中的用途。还提供了该NK细胞作为靶向细胞治疗剂和/或用于过继性癌症免疫治疗的用途。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)